CINECA IRIS Institutional Research Information System

PETRINI, IACOPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.956
AS - Asia 5.013
EU - Europa 3.914
SA - Sud America 637
AF - Africa 297
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.841
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.672
SG - Singapore 1.588
IT - Italia 1.557
CN - Cina 1.509
HK - Hong Kong 599
SE - Svezia 557
BR - Brasile 536
VN - Vietnam 387
DE - Germania 382
GB - Regno Unito 329
BG - Bulgaria 283
CA - Canada 214
FR - Francia 189
JP - Giappone 175
CI - Costa d'Avorio 166
TR - Turchia 154
FI - Finlandia 145
IN - India 142
RU - Federazione Russa 136
KR - Corea 115
UA - Ucraina 77
BD - Bangladesh 63
NL - Olanda 40
AT - Austria 38
IQ - Iraq 38
PK - Pakistan 38
PL - Polonia 35
AR - Argentina 34
BE - Belgio 32
MX - Messico 31
SA - Arabia Saudita 29
ZA - Sudafrica 29
CH - Svizzera 27
ID - Indonesia 23
SN - Senegal 21
ES - Italia 20
PH - Filippine 20
AU - Australia 18
CZ - Repubblica Ceca 18
KE - Kenya 18
UZ - Uzbekistan 18
VE - Venezuela 18
EC - Ecuador 15
MY - Malesia 15
IL - Israele 14
NG - Nigeria 14
MA - Marocco 13
JM - Giamaica 11
EG - Egitto 10
TW - Taiwan 10
CO - Colombia 9
AZ - Azerbaigian 8
OM - Oman 8
TH - Thailandia 8
UY - Uruguay 8
IE - Irlanda 7
LT - Lituania 7
DZ - Algeria 6
GR - Grecia 6
JO - Giordania 6
TT - Trinidad e Tobago 6
IR - Iran 5
LB - Libano 5
NP - Nepal 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
ET - Etiopia 4
HR - Croazia 4
NZ - Nuova Zelanda 4
PA - Panama 4
PE - Perù 4
PS - Palestinian Territory 4
BH - Bahrain 3
BJ - Benin 3
BY - Bielorussia 3
CL - Cile 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
GA - Gabon 3
HN - Honduras 3
HU - Ungheria 3
KG - Kirghizistan 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
CY - Cipro 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
KW - Kuwait 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LY - Libia 2
MD - Moldavia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
Totale 19.819
Salva come PNG Salva come JPEG
Città #
Ashburn 1.045
Woodbridge 892
Singapore 891
Ann Arbor 786
Houston 721
San Jose 646
Fairfield 628
Santa Clara 600
Hong Kong 582
Dallas 465
Chandler 416
Serra 363
Beijing 339
Seattle 292
Sofia 282
Shanghai 275
Milan 223
Wilmington 217
Cambridge 213
New York 202
Boardman 194
Los Angeles 193
London 185
Hefei 174
Abidjan 166
Tokyo 162
Ottawa 157
Princeton 149
Florence 147
Pisa 128
Council Bluffs 124
Lauterbourg 114
Lawrence 111
Medford 111
Seoul 105
Turin 92
Munich 89
Ho Chi Minh City 88
Jacksonville 79
Izmir 77
Des Moines 73
Dearborn 68
Hanoi 67
São Paulo 63
Nanjing 59
Frankfurt am Main 58
Istanbul 57
Buffalo 53
Redondo Beach 50
San Diego 46
Bremen 40
Helsinki 37
Rome 37
Düsseldorf 36
Nuremberg 36
Dong Ket 32
Lancaster 30
Orem 30
Vienna 29
Turku 28
Warsaw 28
Brussels 26
Chicago 26
Nanchang 25
Shenyang 25
Redwood City 24
Chennai 22
Westminster 22
Dakar 21
Rio de Janeiro 21
Columbus 20
Hebei 20
Toronto 20
Multan 19
Washington 19
Changsha 18
Fuzhou 18
Mumbai 18
Phoenix 18
Bern 17
Montreal 17
Tashkent 17
Atlanta 16
Guangzhou 16
Lucca 16
Nairobi 16
Dhaka 15
Manchester 15
Stockholm 15
Johannesburg 14
Kunming 14
Pune 14
Brasília 13
Cascina 13
Da Nang 13
Denver 13
Jiaxing 13
Jüchen 13
Lagos 13
Ogden 13
Totale 14.368
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 323
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 248
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 232
Increased production of inflammatory cytokines by circulating monocytes in mesial temporal lobe epilepsy: A possible role in drug resistance 220
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 217
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 214
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 214
Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation 212
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 209
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 204
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 203
Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow 200
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 198
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 197
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 194
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 192
CD57 and γδ T‐cell receptor expression in nodal metastatic spread of melanoma 191
Oncologia 191
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 189
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 186
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 183
MDS: An Integrated Workup for a Correct Diagnosis 183
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 183
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 181
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 179
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 178
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 177
PET based target volume delineation in hypofractionated radiotherapy in locally advanced NSCLC: A single institution experience 177
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 177
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 176
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 176
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 175
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 174
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 173
Nanotopography Induced Human Bone Marrow Mesangiogenic Progenitor Cells (MPCs) to Mesenchymal Stromal Cells (MSCs) Transition 172
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 170
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer 169
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 169
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 168
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 168
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 167
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 166
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment 165
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 165
Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer. 164
Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results 164
HUMAN MESENCHYMAL CELLS INHIBIT IL2 AND ZOLEDRONATE-INDUCED GAMMA/DELTA T-CELLS. 162
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 159
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: A brief report 158
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors 158
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 157
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer 157
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 156
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 156
A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. 154
Medical treatment of malignant pleural mesothelioma relapses 154
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas 152
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 152
CLONOTYPE AND MUTATIONAL PATTERN IN TCRGD LARGE GRANULAR LYMPHOCYTE LEUKEMIA 150
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer 149
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 148
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 148
Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: A retrospective review of 22 patients 148
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation 148
OCTREOTIDE LAR SUITABLE TREATMENT FOR G1-G2 THORACIC NEUROENDOCRINE TUMORS (T-NET): SINGLE CENTER EXPERIENCE 147
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 146
Mesenchymal Stem Cell in Pancreatic Islet Transplantation 145
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EOSINOPHILOIA IN EGPA FROM HES 145
GAMMA-DELTA T-LYMPHOCYTE SPECIFIC CLONES ARE INVOLVED IN THE GRAFT-VERSUS-MYELOMA AND IN THE GRAFT-VERSUS-HOST DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER NON-MYELOABLATIVE TRANSPLANTATION. 144
Impaired function of gamma-delta lymphocytes in melanoma patients. 144
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 144
Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells 143
NUT rearrangement is uncommon in human thymic epithelial tumors 143
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 142
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 141
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 141
Array comparative genomic hybridization of thymic epithelial tumors identifies loss of CDKN2A as a prognostic factor and BCL2 family members as targets for therapy 140
Mutations of epigenetic regulatory genes are common in thymic carcinomas 140
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma 138
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 138
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment 138
Somatic mutations of thymic epithelial tumors with myasthenia gravis 137
Thymectomy in myasthenic patients with thymoma: killing two birds with one stone 136
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group 135
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors 134
Thymic malignancies: From clinical management to targeted therapies 132
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 132
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 132
Whole Genome and Transcriptome Sequencing of a B3 Thymoma 131
Expression and mutational status of c-kit in thymic epithelial tumors 131
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations 130
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 130
ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach 128
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation 128
Single-cell sequencing has revealed a more complex array of thymic epithelial cells 126
Reproducibility of the WHO classification of thymomas: Practical implications 126
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 125
COMPLETE GENOME SEQUENCING OF A HUMAN B3 THYMOMA 123
ErbB in NSCLC as a molecular target: Current evidences and future directions 121
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 119
Totale 16.374
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.972
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.972
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021219 0 0 0 0 0 0 0 0 0 0 85 134
2021/20221.248 32 72 20 52 232 204 42 35 71 61 71 356
2022/20231.632 207 243 112 103 144 173 22 119 329 11 156 13
2023/20241.482 106 109 174 88 157 277 72 52 15 137 125 170
2024/20254.286 113 149 48 212 471 440 347 168 361 550 559 868
2025/20265.402 382 630 449 536 538 402 965 300 437 637 126 0
Totale 20.331